Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von A Reich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Rapid skin improvement is a key treatment goal of patients with moderate‐to‐severe psoriasis (PsO).
Objectives
To compare the speed of clinical improvement of approved biologics on the symptoms and signs of psoriasis assessed by patients using the validated Psoriasis Symptoms and Signs Diary (PSSD) through 12 weeks.
Methods
Psoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non‐interventional study that compares the effectiveness of anti‐interleukin (IL)‐17A biologics versus other biologics, together with pairwise comparisons of ixekizumab versus five individual biologics in patients with PsO. Using the PSSD 7‐day recall period, patients assessed the symptoms (itch, skin tightness, burning, stinging and pain) and signs (dryness, cracking, scaling, shedding/flaking, redness and bleeding) of their psoriasis (0–10). Symptom and sign summary scores (0–100) are derived from the average of individual scores. Percentage change in summary scores and proportion of patients with clinically meaningful improvements (CMI) in PSSD summary and individual scores are evaluated weekly. Longitudinal PSSD data are reported as observed with treatment comparisons analysed using mixed model for repeated measures (MMRM) and generalized linear mixed models (GLMM).
Results
Across cohorts and treatments, eligible patients ( n = 1654) had comparable baseline PSSD scores. From Week 1, the anti‐IL‐17A cohort achieved significantly larger score improvements in PSSD summary scores and a higher proportion of patients showed CMIs compared to the other biologics cohort through 12 weeks. Lower PSSD scores were associated with a greater proportion of patients reporting their psoriasis as no longer impacting their quality‐of‐life (DLQI 0,1) and a high level of clinical response (PASI100). Results also indicate a relationship between an early CMI in PSSD score at Week 2 and PASI100 score at Week 12.
Conclusions
Treatment with anti‐IL‐17A biologics, particularly ixekizumab, resulted in rapid and sustained patient‐reported improvements in psoriasis symptoms and signs compared with other biologics in a real‐world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Department of Dermatology and Venereology, University Hospital of Zürich and Faculty of Medicine, University of Zürich, Zürich, Switzerland.
- Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada.
- Department of Dermatology and Dermatology Research Unit, Centro Hospitalar Universitário do Porto, University of Porto, Porto, Portugal.
- Eli Lilly and Company, Indiana, Indianapolis, USA.
ORCID-Profile: A Reich, A Pinter, J-T Maul, R B Vender, T Torres, N Haustrup
Förderung
- Eli Lilly and Company
Zitieren
APA
Reich, A., Pinter, A., Maul, J. T., Vender, R. B., Torres, T., Brnabic, A., Haustrup, N., Reed, C., Schuster, C., & Riedl, E. (2023). Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19161
Vancouver
Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, et al. Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19161
BibTeX
@article{Reich2023,
author = {Reich, A and Pinter, A and Maul, J-T and Vender, R B and Torres, T and Brnabic, A and Haustrup, N and Reed, C and Schuster, C and Riedl, E},
title = {Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19161}
}
EUVIMED